Business Context and Reporting Period
This Form 8-K is filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on June 23, 2025. The report details significant operational restructuring, executive departures, and the results of the 2025 Annual Meeting of Stockholders held on June 18, 2025.
Key Financial Metrics
- Cash Position: Approximately $23.3 million in cash and cash equivalents as of May 31, 2025.
- Restructuring Costs: Estimated $3.2 million in costs related to a Reduction in Force (RIF), primarily severance payments.
- Cost Recognition: Majority of RIF costs expected to be recognized in Q3 fiscal year 2025.
- Revenue/Profit: The filing text does not provide specific revenue, profit, or margin figures for the current period.
Material Changes and Operational Actions
- Workforce Reduction: A reduction in force impacting approximately 75% of the current workforce, implemented in two phases:
- Phase 1 (June 30, 2025): Termination of the Chief Operating Officer.
- Phase 2 (July 31, 2025): Termination of the Chief Medical Officer.
- R&D Wind-down: Completion of the DeFianCe clinical trial and cessation of research and development activities for the sirexatamab and FL-501 programs.
- Strategic Review: Initiation of a process to explore strategic options, including a potential sale of the Company or its assets (sirexatamab or FL-501). Raymond James & Associates, Inc. has been engaged as the exclusive financial advisor.
Management Commentary, Risks, and Governance
- Management Commentary: The Board approved these measures due to current market conditions and the Company's financial position to conserve cash.
- Executive Departures: Augustine Lawlor (COO) and Cyndi Sirard, MD (CMO) are being terminated without cause effective June 30 and July 31, 2025, respectively.
- Stockholder Vote Results:
- Director Elections: Thomas Dietz, William Li, and Patricia Martin were elected as Class II directors. Patricia Martin received a significant number of withheld votes (5.1 million).
- Executive Compensation: Advisory vote approved (15.4M For vs. 1.3M Against).
- Auditor Ratification: EisnerAmper LLP ratified for fiscal year 2025.
- Risks: Actual restructuring costs and timing may differ from estimates. The strategic review process does not guarantee a transaction.
Investor Verification Checklist
- Verify the exact timing and final cost of the 75% workforce reduction.
- Monitor the progress of the strategic review process led by Raymond James & Associates.
- Review the updated clinical data for sirexatamab referenced in the press release (Exhibit 99.1).
- Assess the impact of the RIF on the Company's ability to complete the DeFianCe trial.
- Confirm the Company's cash burn rate post-restructuring to evaluate runway.